Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 201 - 250 out of 103,694

Document Document Title
WO/2015/026170A1
The present invention relates to an indole compound represented by formula (1), a pharmaceutically acceptable salt or isomer thereof, a composition for prevention or treatment of necrosis and necrosis-associated diseases, and a method fo...  
WO/2015/025770A1
Provided is a method for screening a pain inhibitor, characterized by comprising using netrin-4 and/or a netrin-4 receptor and selecting a substance that suppresses the signal transduction downstream of netrin-4. According to the screeni...  
WO/2015/025718A1
The present invention is an adhesive patch which is provided with a supporting body and an adhesive layer that is arranged on at least one surface of the supporting body and is formed of an adhesive composition containing a medical agent...  
WO/2015/025172A1
The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain 5-aryl-thiazol-2-yl-amine compounds of the following formula (I) (for convenience, collectively referred to herein as "5AT2A...  
WO/2015/025980A1
A method for treating neuropathic pain in a mammalian subject, which comprises administering an effective amount of a fatty acid derivative, is provided.  
WO/2015/027146A1
A systematic screening has revealed a family of compounds that exhibit inhibitory effects on 12/15-lipoxygenase. Accordingly, the present invention relates to the use of these compounds for the inhibition of 12/15-lipoxygenase and for th...  
WO/2015/026339A1
This application discloses a composition comprising an amiloride and/or an amiloride analog which can be used for reducing nerve injury or nervous system injury in a subject. The formulation of such composition is also disclosed. The app...  
WO/2015/025323A1
A pharmaceutical composition and method for treating or attenuating a mood or stress-related disorder in a subject having normal or low inflammatory state is provided. In some embodiments, the pharmaceutical composition and method of the...  
WO/2015/025902A1
Provided is a nasal brain function regulator which acts on specific places in a subject's brain using the sense of smell to stimulate or suppress activity of the specific places in the brain, the regulator comprising, as an active ingred...  
WO/2015/023937A1
Provided herein are oligonucleotides that are useful for modulating the heterochromatin state of genes; related compositions and methods are also provided. In some embodiments, methods are provided for treating a disease associated with ...  
WO/2015/023244A1
The invention relates to medicine and to the chemical and pharmaceutical industry, in particular for creating, producing and using cerebro-protective agents for treating and improving blood circulation in the brain. The drug comprises 12...  
WO/2015/023816A1
The present invention is directed to (-)-(2R,3S)-2-amino-3-hydroxy-3-pyridin-4-yl-1-pyrrolidin-1- yl-propan-1-one (L)-(+) tartrate salt, a pharmaceutical composition comprising said salt, a process for making said salt, and the use of sa...  
WO/2015/023054A1
The present invention relates to an animal model with obsessive compulsive disorder, manufactured by deficiency of Ninjurin 1, and a method for searching candidate drugs for preventing or treating obsessive compulsive disorder using the ...  
WO/2015/023901A1
This disclosure provides isolated cells and compositions comprising one or more isolated cell(s) as described herein. In one aspect, the isolated cell is a pre-term placenta-derived stem cell (also referred to placenta-derived multi pote...  
WO/2015/021943A1
Provided is a method of promoting neurogenesis by administration of an agent that enhance Axin's expression, stability, and/or activity, such as through administration of a tankyrase inhibitor. Further provided are compositions and kits ...  
WO/2015/023289A1
Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula (I) as follows: wherein R1, R2, R3, and G are defined herein.  
WO/2015/023142A1
The present invention provides a pharmaceutical composition or a food composition comprising, as active ingredients, flavone-6-C-glucose derivatives or galenical extracts containing flavone-6-C-glucose derivatives. The composition of the...  
WO/2015/021535A1
The disclosure provides methods and uses for alleviating and/or treating pain including pain disorders using melatonin ligands of Formula I: or pharmaceutically acceptable salts thereof wherein: n is 1 or 2; m is 0, 1 or 2; p is 0, 1, 2,...  
WO/2015/022830A1
[Problem] To provide: a composition that is for promoting estrogen secretion and that can promote the secretion of estrogen; an estrogen secretion aromatic composition; and an estrogen aroma tool. [Solution] By means of a method mediated...  
WO/2015/022038A1
Compounds of formula (I) in which R, W, R1, R4, X1, X2, X3, X4 and q have the meanings indicated in Claim 1, are inhibitors of fatty acid synthase, and can be employed, inter alia, for the treatment of diseases such as cancer, cardiovasc...  
WO/2015/021904A1
Disclosed is a method for synthesizing glatiramer acetate. The present method uses two or multiple depolymerization steps to control the average molecular weight of the glatiramer acetate product within a relatively narrow range.  
WO/2015/023890A1
A glycosylated pleiotropic peptide pituitary adenylate cyclase-activating polypeptide (PACAP) which can both agonize PAC, receptors, causing neuroprotective effects, and antagonize VPAC receptors, causing anti-inflammation in several mod...  
WO/2015/023871A1
Alcoholism, and symptoms and negative effects thereof may be treated using ibudilast or a pharmaceutically acceptable salt thereof. Abstinence from alcohol consumption may be maintained using ibudilast or a pharmaceutically acceptable sa...  
WO/2015/022418A1
This invention relates to the treatment of varying degrees of cognitive impairment associated with, for example, aging, Alzheimer's disease, schizophrenia with low dose administration of a PDE4 inhibitor, specifically roflumilast.  
WO/2015/023593A1
This disclosure relates to progesterone phophate derivatives and uses related thereto. In certain embodiments, the disclosure relates to compounds disclosed herein and uses for managing inflammation such as those resulting from traumatic...  
WO/2015/022831A1
[Problem] To provide: a composition for promoting estrogen secretion and that is able to promote estrogen secretion; an estrogen secretion aromatic composition; and an estrogen aromatic tool. [Solution] The composition that is for promot...  
WO/2015/022417A1
Treatment of varying degrees of cognitive impairment associated with Alzheimer's disease with a combination of a phosphodiesterase 4 inhibitor and an acetylcholinesterase inhibitor, including roflumilast and donepezil hydrochloride.  
WO/2015/023244A9
The invention relates to medicine and to the chemical and pharmaceutical industry, in particular for creating, producing and using cerebro-protective agents for treating and improving blood circulation in the brain. The drug comprises 12...  
WO/2015/020565A1
This invention relates to novel compounds - substituted [1,2,4]-triazolo[4,3-а]pyridines of general formula (I), or the pharmaceutically acceptable salts thereof, where A is an unsubstituted or substituted aminocarbonyl group -N-С(...  
WO/2015/020241A1
The present invention relates to a composition containing a Galla rhois extract as an active ingredient for improving cognition, and more specifically, to a composition containing a Galla rhois extract as an active ingredient, for preven...  
WO/2015/021191A1
In accordance with the present invention, there are provided formulations of gamma secretase modulators (GSMs) which are suitable for oral delivery and have improved transport properties relative to prior art formulations thereof. Also p...  
WO/2015/020234A1
The present invention provides a method for more efficiently producing high-quality dopaminergic neurons from neuron precursor cells. More specifically, the present invention provides a method for producing dopaminergic neurons, which is...  
WO/2015/018375A1
Provided in the present invention are a depression regulatory factor and applications thereof. Specifically, provided in the present invention are applications of βCaMKII inhibitor in preparation of a medicament for prevention and/or tr...  
WO/2015/021187A1
Provided are mutant cocaine esterase polypeptides and PEGylated formulations thereof.  
WO/2015/018029A1
The present invention is directed to oxazole compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the oxazole compounds described herein in the potential treatment or prevention of neurol...  
WO/2015/019334A1
The present invention relates to pharmaceutical compositions having analgesic and/or anti- inflammatory effect comprising the combination of diosmin and hesperidin, and the use of said composition for the treatment of pain; e.g., moderat...  
WO/2015/018356A1
The present invention discloses a diarylhydantoin derivative, and preparation method, pharmaceutical composition, and application thereof. The present invention provides a diarylhydantoin derivative as represented by formula I, a pharmac...  
WO/2015/018827A1
The present invention is related to NDP-MSH or pharmaceutically acceptable salts thereof for therapeutic and/or prophylactic therapeutic treatment of inflammatory and/or neurodegenerative disorders of the CNSor multiple sclerosis. The pr...  
WO/2015/018475A1
Compounds of the formula I in which R1-R3 have the meanings indicated in Claim 1, are inhibitors of Tankyrase, and can be employed, inter alia, for the treatment of diseases such as cancer, cardiovascular diseases, central nervous system...  
WO/2015/020545A3
The invention discloses new derivatives of N-[(phenoxy)ethoxy]alkylaminoalkanols with the structure which show pharmacological activity, especially in therapy and/or prophylaxis disorders and/or symptoms withneurological etiology.  
WO/2015/017900A1
The present disclosure relates generally to a protocol to treat or prevent diseases or conditions associated with pathological forms of amyloid beta (Aβ), including Alzheimer's disease. Enabled herein is a reagent for use in the treatme...  
WO/2015/016392A1
The purpose of the present invention is to provide a method for detecting ALS. The present invention pertains to an ALS detection method characterized in that of the ERBB4 gene base sequence sampled from a subject, the genetic alteration...  
WO/2015/014768A1
The present invention relates to compounds of general formula (I) wherein R1 is phenyl or pyridinyl, which are optionally substituted by one, two or three substituents, selected from halogen, lower alkyl substituted by halogen, lower alk...  
WO/2015/016206A1
The present invention provides a prophylactic or therapeutic agent for autoimmune disease (e.g., psoriasis, rheumatoid arthritis, inflammatory bowel disease, Sjogren's syndrome, Behcet's disease, multiple sclerosis, systemic lupus erythe...  
WO/2015/013865A1
Disclosed are agomelatine sulfonic acids complexes having the specific stoichiometry of 2 molar equivalents of agomelatine for 1 molar equivalent of sulfonic acids. Those complexes show excellent solubility, stability and purity, making ...  
WO/2015/014838A1
The present invention relates to an inhibitor of neurocalcin delta (NCALD) for use in a method for the treatment or prevention of a patient suffering from a disorder associated with a pathological calcium homeostasis. Furthermore, the pr...  
WO/2015/016695A1
The present invention relates to stable pharmaceutical compositions comprising a tablet/tablet system, consisting of the compression of a tablet within another tablet with a biphasic-delivery system of at least one analogue of (1R, 2R)-2...  
WO/2015/017280A1
The present invention relates to compositions and methods for the prevention and treatment of neurodegenerative diseases, such Alzheimer's disease, that are caused by misfolding, aggregating proteins. The compositions and methods of the ...  
WO/2015/014816A1
The invention refers to compounds of general formula (I) wherein the variables take various meanings, pharmaceutical compositions containing them and their use in medicine, particularly in pain therapy.  
WO/2015/017412A1
The disclosure includes compounds and pharmaceutically acceptable salts of Formula (I). Certain compounds and salts of Formula (I) are selective inhibitors of the Dopamine D2 receptor. The variables R1-R4, n, and L are defined herein. Th...  

Matches 201 - 250 out of 103,694